{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:09:22Z","timestamp":1759018162398,"version":"3.44.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jinf.2016.04.018","type":"journal-article","created":{"date-parts":[[2016,5,21]],"date-time":"2016-05-21T03:25:07Z","timestamp":1463801107000},"page":"S23-S28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S","title":["Preventing cervical cancer and genital warts \u2013 How much protection is enough for HPV vaccines?"],"prefix":"10.1016","volume":"72","author":[{"given":"Margaret","family":"Stanley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.jinf.2016.04.018_bib1","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","volume":"30","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.jinf.2016.04.018_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.virol.2013.04.023","article-title":"Cross-roads in the classification of papillomaviruses","volume":"445","author":"de Villiers","year":"2013","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.jinf.2016.04.018_bib3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"de Martel","year":"2012","journal-title":"Lancet Oncol"},{"issue":"Suppl 10","key":"10.1016\/j.jinf.2016.04.018_bib4","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1016\/j.vaccine.2008.05.064","article-title":"Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia","volume":"26","author":"Bosch","year":"2008","journal-title":"Vaccine"},{"issue":"Suppl 5","key":"10.1016\/j.jinf.2016.04.018_bib5","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"10.1016\/j.jinf.2016.04.018_bib6","article-title":"Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6\/11 disease","volume":"24","author":"Lacey","year":"2006","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.jinf.2016.04.018_bib7","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1086\/522863","article-title":"The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries","volume":"196","author":"Kjaer","year":"2007","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.jinf.2016.04.018_bib8","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/ijc.27485","article-title":"Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer","volume":"131","author":"Guan","year":"2012","journal-title":"Int J Cancer"},{"issue":"13","key":"10.1016\/j.jinf.2016.04.018_bib9","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.ejca.2015.06.001","article-title":"Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions","volume":"51","author":"Serrano","year":"2015","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jinf.2016.04.018_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jinf.2016.04.018_bib11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jinf.2016.04.018_bib12","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"10.1016\/j.jinf.2016.04.018_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age","volume":"105","author":"Castellsague","year":"2011","journal-title":"Br J Cancer"},{"issue":"Suppl 3","key":"10.1016\/j.jinf.2016.04.018_bib14","first-page":"S3\/42","article-title":"Chapter 5: updating the natural history of HPV and anogenital cancer","volume":"24","author":"Moscicki","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jinf.2016.04.018_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.jinf.2016.04.018_bib16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malagon","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2016.04.018_bib17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/1741-7015-11-227","article-title":"Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study","volume":"11","author":"Gertig","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.jinf.2016.04.018_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1458","article-title":"Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia","volume":"348","author":"Crowe","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2016.04.018_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.jinf.2016.04.018_bib20","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/bjc.2014.479","article-title":"Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland","volume":"111","author":"Pollock","year":"2014","journal-title":"Br J Cancer"},{"issue":"Suppl 5","key":"10.1016\/j.jinf.2016.04.018_bib21","doi-asserted-by":"crossref","first-page":"F83","DOI":"10.1016\/j.vaccine.2012.04.106","article-title":"Human papillomavirus vaccines \u2013 immune responses","volume":"30","author":"Stanley","year":"2012","journal-title":"Vaccine"},{"issue":"Feb 21. 4","key":"10.1016\/j.jinf.2016.04.018_bib22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnci\/93.4.284","article-title":"Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine","volume":"93","author":"Harro","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.jinf.2016.04.018_bib23","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1158\/0008-5472.CAN-11-0751","article-title":"Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men","volume":"72","author":"Lu","year":"2012","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.jinf.2016.04.018_bib24","doi-asserted-by":"crossref","first-page":"e74797","DOI":"10.1371\/journal.pone.0074797","article-title":"Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses","volume":"8","author":"Scherpenisse","year":"2013","journal-title":"PLoS One"},{"issue":"27\u201328 Jul 7","key":"10.1016\/j.jinf.2016.04.018_bib25","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"issue":"9447","key":"10.1016\/j.jinf.2016.04.018_bib26","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"9518","key":"10.1016\/j.jinf.2016.04.018_bib27","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jinf.2016.04.018_bib28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/CVI.05208-11","article-title":"Immunogenicity of the quadrivalent human papillomavirus (type 6\/11\/16\/18) vaccine in males 16 to 26 years old","volume":"19","author":"Hillman","year":"2012","journal-title":"Clin Vaccin Immunol CVI"},{"issue":"41","key":"10.1016\/j.jinf.2016.04.018_bib29","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1016\/j.vaccine.2009.07.027","article-title":"Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine","volume":"27","author":"Rowhani-Rahbar","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2016.04.018_bib30","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4161\/hv.18865","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up","volume":"8","author":"Roteli-Martins","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"26","key":"10.1016\/j.jinf.2016.04.018_bib31","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jinf.2016.04.018_bib32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.vaccine.2012.09.037","article-title":"Immune responses elicited by a fourth dose of the HPV-16\/18 AS04-adjuvanted vaccine in previously vaccinated adult women","volume":"31","author":"Moscicki","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jinf.2016.04.018_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcv.2011.12.009","article-title":"Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine","volume":"53","author":"Rowhani-Rahbar","year":"2012","journal-title":"J Clin Virol"},{"issue":"12","key":"10.1016\/j.jinf.2016.04.018_bib34","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4161\/hv.7.12.18281","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 vaccine and HPV-6\/11\/16\/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years","volume":"7","author":"Einstein","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.jinf.2016.04.018_bib35","first-page":"915","article-title":"Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997\u20132012","volume":"25","author":"Baldur-Felskov","year":"2015","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.jinf.2016.04.018_bib36","doi-asserted-by":"crossref","first-page":"f2032","DOI":"10.1136\/bmj.f2032","article-title":"Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data","volume":"346","author":"Ali","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2016.04.018_bib37","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/infdis\/jis590","article-title":"Fall in human papillomavirus prevalence following a national vaccination program","volume":"206","author":"Tabrizi","year":"2012","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.jinf.2016.04.018_bib38","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1038\/bjc.2014.198","article-title":"Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16\/18 and closely related HPV types","volume":"110","author":"Kavanagh","year":"2014","journal-title":"Br J Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.jinf.2016.04.018_bib39","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.ypmed.2011.08.015","article-title":"Adolescent and young adult HPV vaccination in Australia: achievements and challenges","volume":"53","author":"Garland","year":"2011","journal-title":"Prev Med"},{"issue":"12","key":"10.1016\/j.jinf.2016.04.018_bib40","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1093\/annonc\/mdr015","article-title":"Worldwide burden of cervical cancer in 2008","volume":"22","author":"Arbyn","year":"2011","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jinf.2016.04.018_bib41","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1086\/521679","article-title":"Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine","volume":"196","author":"Giuliano","year":"2007","journal-title":"J Infect Dis"},{"issue":"17","key":"10.1016\/j.jinf.2016.04.018_bib42","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jinf.2016.04.018_bib43","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study","volume":"7","author":"Romanowski","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.jinf.2016.04.018_bib44","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1016\/j.vaccine.2014.04.005","article-title":"Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or the licensed three-dose schedule","volume":"32","author":"Boxus","year":"2014","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.jinf.2016.04.018_bib45","first-page":"221","article-title":"Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 \u2013 conclusions and recommendations","volume":"89","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"issue":"19","key":"10.1016\/j.jinf.2016.04.018_bib46","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.jinf.2016.04.018_bib47","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1470-2045(15)00047-9","article-title":"Efficacy of fewer than three doses of an HPV-16\/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials","volume":"16","author":"Kreimer","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jinf.2016.04.018_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju436","article-title":"The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents","volume":"107","author":"Kreimer","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jinf.2016.04.018_bib49","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1741-7015-9-54","article-title":"Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models","volume":"9","author":"Jit","year":"2011","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.jinf.2016.04.018_bib50","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus l1 virus-like particle vaccine in the costa rica vaccine trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"issue":"3","key":"10.1016\/j.jinf.2016.04.018_bib51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2010.08.003","article-title":"In\u00a0vivo mechanisms of vaccine-induced protection against HPV infection","volume":"8","author":"Day","year":"2010","journal-title":"Cell Host Microbe"},{"issue":"24","key":"10.1016\/j.jinf.2016.04.018_bib52","doi-asserted-by":"crossref","first-page":"13253","DOI":"10.1128\/JVI.06093-11","article-title":"A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection","volume":"85","author":"Longet","year":"2011","journal-title":"J Virol"},{"issue":"Suppl 1","key":"10.1016\/j.jinf.2016.04.018_bib53","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1086\/425271","article-title":"Role of herd immunity in determining the effect of vaccines against sexually transmitted disease","volume":"191","author":"Garnett","year":"2005","journal-title":"J Infect Dis"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445316300457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445316300457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:24:06Z","timestamp":1759008246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445316300457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":53,"alternative-id":["S0163445316300457"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2016.04.018","relation":{},"ISSN":["0163-4453"],"issn-type":[{"type":"print","value":"0163-4453"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preventing cervical cancer and genital warts \u2013 How much protection is enough for HPV vaccines?","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2016.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}